Abstract: Described herein are cell lines for recombinant adeno-associated virus (AAV) production, cell lines for AAV-implemented protein production, and cell lines for use in titering AAV; methods of making each of those cell lines; and methods of using each of those cell lines. In some aspects, the cell lines disclosed herein may be used in a manufacturing process that is seed virus-free, helper virus-free, and transfection-free that uses synthetic elements to control viral genes in a stable cell line.

Abstract: The invention is directed to compositions of cell aggregates and methods for making and using the cell aggregates where the aggregates comprise cells that are not embryonic stem cells but can differentiate into cell types of at least two of ectodermal, endodermal, and mesodermal embryonic germ layers, e.g., stem cells.

Abstract: This disclosure describes a system for generating influenza virus or influenza virus proteins, methods of making that system, and methods of using that system.

Abstract: The invention is directed to compositions of cell aggregates and methods for making and using the cell aggregates where the aggregates comprise cells that are not embryonic stem cells but can differentiate into cell types of at least two of ectodermal, undo dermal, and mesodermal embryonic germ layers, e.g., stem cells.

Abstract: The invention is directed to compositions of cell aggregates and methods for making and using the cell aggregates where the aggregates comprise cells that are not embryonic stem cells but can differentiate into cell types of at least two of ectodermal, undo dermal, and mesodermal embryonic germ layers, e.g., stem cells.

Abstract: The invention is directed to compositions of cell aggregates and methods for making and using the cell aggregates where the aggregates comprise cells that are not embryonic stem cells but can differentiate into cell types of at least two of ectodermal, endodermal, and mesodermal embryonic germ layers, e.g., stem cells.

Abstract: Cell lines that overexpress lactate dehydrogenase C (LDH-C) are disclosed. Generally, the cells include a heterologous polynucleotide molecule that encodes a LDH-C polypeptide or a fragment or biologically active analog that possesses measurable LDH-C activity. Also disclosed is a method of increasing the productive yield of a cell that produces a therapeutic agent. Generally, the method includes introducing into the cell a heterologous polynucleotide molecule that encodes a LDH-C polypeptide or a fragment or biologically active analog that possesses measurable LDH-C activity.

Abstract: The invention is directed to compositions of cell aggregates and methods for making and using the cell aggregates where the aggregates comprise cells that are not embryonic stem cells but can differentiate into cell types of at least two of ectodermal, endodermal, and mesodermal embryonic germ layers, e.g., stem cells.

Abstract: The invention is directed to compositions of cell aggregates and methods for making and using the cell aggregates where the aggregates comprise cells that are not embryonic stem cells but can differentiate into cell types of at least two of ectodermal, endodermal, and mesodermal embryonic germ layers, e.g., stem cells.

Abstract: The invention is directed to compositions of cell aggregates and methods for making and using the cell aggregates where the aggregates comprise cells that are not embryonic stem cells but can differentiate into cell types of at least two of ectodermal, undo dermal, and mesodermal embryonic germ layers, e.g., stem cells.

Abstract: The invention is directed to compositions of cell aggregates and methods for making and using the cell aggregates where the aggregates comprise cells that are not embryonic stem cells but can differentiate into cell types of at least two of ectodermal, endodermal, and mesodermal embryonic germ layers, e.g., stem cells.

Abstract: Gene complementation is used to restore cholesterol independence in NS lineage murine myeloma cells, such as NS0 and NS 1, yielding a selectable system for recombinant production of polynucleotides and polypeptides.

Abstract: The invention is directed to compositions of cell aggregates and methods for making and using the cell aggregates where the aggregates comprise cells that are not embryonic stern cells but can differentiate into cell types of at least two of ectodermal, undo dermal, and mesodermal embryonic germ layers, e.g., stem cells.

Abstract: Gene complementation is used to restore cholesterol independence in NS lineage murine myeloma cells, such as NSO and NS 1, yielding a selectable system for recombinant production of polynucleotides and polypeptides.

Abstract: A biomimetic nanocomposite including hydroxyapatite nanocrystals, gelatin, and polymer, wherein the biomimetic nanocomposite is crosslinked is described. Also described is a process for making the nanocomposite. Additionally, a method for using the nanocomposite, and articles formed from the nanocomposite are also described.

Abstract: Disruption of the two-component regulatory system encoded by the cbsA locus is associated with improved production of cephamycin C and/or clavulanic acid in Streptomyces clavuligerus.

Abstract: A method for cultivating cells is provided effective to adapt the cells to a metabolic state characterized by low lactate production, thus making possible sustained high cell densities in continuous culture.

Abstract: Methods of maintaining animal cells for product production, for supporting hepatocyte function and viability to treat a patient suffering from hepatic failure and for preserving tissue-specific function of mammalian cells are carried out with a bioreactor containing a feed and waste chamber and a cell chamber separated by a selectively permeable membrane. Within the cell chamber, a biocompatible contracted three-dimensional gel matrix entraps animal cells or genetic modifications thereof, and a liquid phase contains a concentrated solution of the cell product. The bioreactor uses only two chambers to achieve three distinct zones within the bioreactor. The bioreactor can be of either hollow fiber or flat-bed configuration. In the configuration using hollow fibers, the two fluid paths correspond to the cavity surrounding the hollow fibers (the extracapillary space), and to the lumens of the hollow fibers themselves. Both fluid paths have inlet and outlet ports.

Abstract: A bioreactor apparatus comprising two chambers, a feed and waste chamber and a cell chamber separated by a selectively permeable membrane. Within the cell chamber, a biocompatible three-dimensional matrix entraps animal cells or genetic modifications thereof. Due to the presence of this biocompatible matrix, the cell chamber generally has a gel phase, i.e., the biocompatible matrix and cells, and a liquid phase containing a concentrated solution of the cell product to be harvested. Thus, the bioreactor of this invention uses only two chambers to achieve three distinct zones within the apparatus. A bioartificial liver is based on a bioreactor of the type having two fluid paths separated by a permeable medium. The bioreactor can be of either hollow fiber or flat-bed configuration. In the configuration using hollow fibers, the two fluid paths correspond to the cavity surrounding the hollow fibers (the extracapillary space), and to the lumens of the hollow fibers themselves.

Abstract: A filter device containing cell masses and single cells is described. The device contains porous hollow fibers and hepatocytes entrapped within a contracted gel matrix.